PATIENT-CENTRIC IN ALL WE DO
Biohaven is a modern pharmaceutical company that is guided by science and inspired to change the lives of people with unmet medical needs.
CHALLENGING THE STATUS QUO
At Biohaven, we are committed to discovering, developing, and commercializing life-changing new therapies for people with debilitating diseases. Leveraging our proprietary platforms, we are advancing paradigm-shifting treatment options to improve the lives of people with debilitating neurological and neuropsychiatric diseases, including rare disorders and a broad range of adjacent indications.
We have made rapid progress with multiple compounds across our portfolio including our glutamate modulator and myostatin platforms.
Multiple clinical trials are ongoing for product candidates across neurological conditions such as obsessive compulsive disorder (OCD) and spinal muscular atrophy (SMA).
WINNING WITH SCIENCE
Biohaven is dedicated to following science, continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital.
Katy M.
Katy M.Senior Research Scientist
WINNING WITH SCIENCE
Biohaven is dedicated to following science, continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital.
Katy M.
Senior Research Scientist
PROVEN DRUG DEVELOPMENT CAPABILITIES
Biohaven is developing drug candidates based on its proprietary, next-generation bispecific technology platforms, all of which are modular in design to enable rapid generation of novel therapies for the treatment of diseases with high unmet medical needs.
Our robust research capabilities complement our late-stage clinical development and commercial expertise and expands our focus beyond neuroscience to other strategic disease adjacencies including chronic pain, cancer, and infectious disease.
DEMONSTRATING THE POWER OF DIGITAL TRANSFORMATION
As a modern pharmaceutical company, Biohaven also has established an agile operating model with a culture of innovation that extends across the R&D lifecycle to all aspects of business. We pride ourselves on being a tech-savvy company and a leader in the use of digital tools and technologies to increase engagement and enhance the success of our novel treatments.
REALIZING OUR MISSION
We believe our future is bright. We intend to realize our mission by delivering a paradigm shift by creating opportunities for breakthrough science with our early-stage R&D engine, executing diligently on our commercial launches, harnessing our digital technology leadership, and building our global partnerships.
We’re just getting started.